316 related articles for article (PubMed ID: 21999340)
21. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction.
Prabhasawat P; Tesavibul N; Mahawong W
Cornea; 2012 Dec; 31(12):1386-93. PubMed ID: 23135530
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management.
Sullivan BD; Crews LA; Sönmez B; de la Paz MF; Comert E; Charoenrook V; de Araujo AL; Pepose JS; Berg MS; Kosheleff VP; Lemp MA
Cornea; 2012 Sep; 31(9):1000-8. PubMed ID: 22475641
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye.
Guzey M; Karaman SK; Satici A; Ozardali I; Sezer S; Bozkurt O
Clin Exp Ophthalmol; 2009 Aug; 37(6):541-9. PubMed ID: 19702702
[TBL] [Abstract][Full Text] [Related]
24. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye.
Roberts CW; Carniglia PE; Brazzo BG
Cornea; 2007 Aug; 26(7):805-9. PubMed ID: 17667613
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
Huang JF; Yafawi R; Zhang M; McDowell M; Rittenhouse KD; Sace F; Liew SH; Cooper SR; Pickering EH
Ophthalmology; 2012 Jul; 119(7):e43-50. PubMed ID: 22607938
[TBL] [Abstract][Full Text] [Related]
26. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A.
Brignole F; Pisella PJ; De Saint Jean M; Goldschild M; Goguel A; Baudouin C
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):90-5. PubMed ID: 11133852
[TBL] [Abstract][Full Text] [Related]
27. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
[TBL] [Abstract][Full Text] [Related]
28. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome.
Yoon KC; Heo H; Im SK; You IC; Kim YH; Park YG
Am J Ophthalmol; 2007 Jul; 144(1):86-92. PubMed ID: 17493572
[TBL] [Abstract][Full Text] [Related]
29. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
[TBL] [Abstract][Full Text] [Related]
30. A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye.
Gehlsen U; Braun T; Notara M; Krösser S; Steven P
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):767-775. PubMed ID: 28091781
[TBL] [Abstract][Full Text] [Related]
31. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
32. [A 0,05% cyclosporine treatment of the advanced dry eye syndrome].
Kujawa A; Rózycki R
Klin Oczna; 2005; 107(4-6):280-6. PubMed ID: 16118939
[TBL] [Abstract][Full Text] [Related]
33. The effect of topical cyclosporine A on clinical findings and cytological grade of the disease in patients with dry eye.
Sahli E; Hoşal BM; Zilelioğlu G; Gülbahçe R; Ustün H
Cornea; 2010 Dec; 29(12):1412-6. PubMed ID: 20847673
[TBL] [Abstract][Full Text] [Related]
34. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation.
Cordero-Coma M; Anzaar F; Sobrin L; Foster CS
Ocul Immunol Inflamm; 2007; 15(2):99-104. PubMed ID: 17558834
[TBL] [Abstract][Full Text] [Related]
35. Short term effects of topical cyclosporine and viscoelastic on the ocular surfaces in patients with dry eye.
Moon JW; Lee HJ; Shin KC; Wee WR; Lee JH; Kim MK
Korean J Ophthalmol; 2007 Dec; 21(4):189-94. PubMed ID: 18063881
[TBL] [Abstract][Full Text] [Related]
36. A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye.
Park Y; Song JS; Choi CY; Yoon KC; Lee HK; Kim HS
J Ocul Pharmacol Ther; 2017 Mar; 33(2):66-72. PubMed ID: 27929721
[TBL] [Abstract][Full Text] [Related]
37. Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness.
Benelli U; Nardi M; Posarelli C; Albert TG
Cont Lens Anterior Eye; 2010 Apr; 33(2):61-7. PubMed ID: 20153684
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.
Pucci N; Novembre E; Cianferoni A; Lombardi E; Bernardini R; Caputo R; Campa L; Vierucci A
Ann Allergy Asthma Immunol; 2002 Sep; 89(3):298-303. PubMed ID: 12269651
[TBL] [Abstract][Full Text] [Related]
39. Dry eye symptoms following cataract surgery.
Roberts CW; Elie ER
Insight; 2007; 32(1):14-21; quiz 22-3. PubMed ID: 17533782
[TBL] [Abstract][Full Text] [Related]
40. The application of autologous serum eye drops in severe dry eye patients; subjective and objective parameters before and after treatment.
Jirsova K; Brejchova K; Krabcova I; Filipec M; Al Fakih A; Palos M; Vesela V
Curr Eye Res; 2014 Jan; 39(1):21-30. PubMed ID: 24074049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
